Hansa Biopharma AB (publ) reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was SEK 22.84 million compared to SEK 67.08 million a year ago. Net loss was SEK 250.66 million compared to SEK 153.95 million a year ago. Basic loss per share from continuing operations was SEK 4.78 compared to SEK 3.45 a year ago. Diluted loss per share from continuing operations was SEK 4.78 compared to SEK 3.45 a year ago.
For the nine months, sales was SEK 83.68 million compared to SEK 123.76 million a year ago. Net loss was SEK 707.26 million compared to SEK 462.46 million a year ago. Basic loss per share from continuing operations was SEK 13.49 compared to SEK 10.39 a year ago. Diluted loss per share from continuing operations was SEK 13.49 compared to SEK 10.39 a year ago.